- Home
- UAC vs GNLX Comparison
UAC vs GNLX Comparison
Compare UAC & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
HOLD
Current Price
$2.60
Company Overview
Basic Information| Metric | UAC | GNLX |
|---|---|---|
| Founded | 2025 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 137.6M | 110.4M |
| IPO Year | 2025 | 2022 |
Fundamental Metrics
Financial Performance| Metric | UAC | GNLX |
|---|---|---|
| Price | $9.97 | $2.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $17.25 |
| AVG Volume (30 Days) | 202.3K | ★ 297.0K |
| Earning Date | N/A | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 9.47 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.51 | $2.29 |
| 52 Week High | $9.99 | $8.54 |
Technical Indicators
Market Signals| Indicator | UAC | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 57.39 | 41.79 |
| Support Level | $9.51 | $2.30 |
| Resistance Level | $9.99 | $2.95 |
| Average True Range (ATR) | 0.01 | 0.15 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 83.33 | 21.43 |
Price Performance
Historical Comparison UAC
GNLX
About GNLX Genelux Corporation
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.